Ly M. Nguyen
Health Professions · University of Michigan
Publications
69
Citations
1,987
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1993
Typically publishes in teams of ~17 · 11% small-team papers (≤3 authors) · across 15 venues
- Double nano-emulsions for stabilizing Vitamin C and enhancing antioxidant capacity with macadamia oil and tea tree essential oil
Oil Crop Science · 2025
- Somatization and Hypervigilance: The Influence of Colorism and Discrimination Among Asian, Latinx, and Black University Students
Journal of College Student Mental Health · 2025
- Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
Journal of Immunotherapy and Precision Oncology · 2025
- FACTORS INFLUENCING THE SPEECH ACT OF REFUSALS OF OFFERS BY NATIVE SPEAKERS OF AMERICAN ENGLISH AND VIETNAMESE PEOPLE
SCIENTIFIC JOURNAL OF TAN TRAO UNIVERSITY · 2025
- Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
Journal of Clinical Oncology · 2023
- Supplementary Tables S1 and S2 from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
2023
- Supplementary Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
2023
- Data from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
2023
- Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
2023
- Data from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
2023
- Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
2023
- Supplementary Tables S1 and S2 from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
2023
- Supplementary Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
2023
- Morphological characterizations of bud, anther and microspores in Ngoc Linh ginseng - Panax vietnamensis Ha et Grushv. var. vietnamensis (Araliaceae)
Pakistan Journal of Botany · 2022
- A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Clinical Cancer Research · 2021
- Journal of Clinical Oncology×3
- British Journal of Cancer×2
- Investigational New Drugs×2
- Clinical Cancer Research×1
- Oil Crop Science×1
- Loni C. Arrese
Health Professions · The Ohio State University
- Krupa Patel
Health Professions · University of Michigan
- B Jones
Health Professions · Indiana University
- Georgia A. Malandraki
Health Professions · Purdue University West Lafayette
- Apoorva T. Ramaswamy
Health Professions · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile